Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation

AIMS: The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial allowed patients who completed the trial receiving their assigned dabigatran 150 mg (D150) or 110 mg (D110) twice a day to continue into the Long-term Multicenter Extension of Dabigatran Treatment in Patients with Atr...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Europace
Hlavní autoři: Ezekowitz, Michael D., Eikelboom, John, Oldgren, Jonas, Reilly, Paul A., Brueckmann, Martina, Kent, Anthony P., Pogue, Janice, Spahr, Judith, Clemens, Andreas, Noack, Herbert, Diener, Hans-Christoph, Wallentin, Lars, Yusuf, Salim, Connolly, Stuart J.
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2016
Témata:
Clinical Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4927062/
https://ncbi.nlm.nih.gov/pubmed/26944733
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/europace/euv312
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky